NCT05226507TerminatedPhase 1
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma, Inc.37 sites in 2 countries45 target enrollmentStarted: December 31, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Nuvectis Pharma, Inc.
- Enrollment
- 45
- Locations
- 37
- Primary Endpoint
- Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities
Study Overview
Brief Summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Detailed Description
Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies.
In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Part A Inclusion Criteria:
- •Provide written informed consent.
- •18 years old or older.
- •Life expectancy of at least 12 weeks.
- •Histologically- or cytologically-confirmed, advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator (in Part B, subjects with specific cancer types will be enrolled; Specific criteria will be introduced in a protocol amendment).
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
Exclusion Criteria
- •Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP
- •Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
- •Ongoing toxic manifestations of previous treatments > Grade
- •Subjects with treated brain metastases are eligible if there is no evidence of progression for at least 28 days after central nervous system (CNS) directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
- •Female subjects who can become pregnant (or are already pregnant or lactating).
- •Male subjects with partners of childbearing potential (unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence).
- •Part B Inclusion Criteria:
- •Provide written informed consent.
- •18 years old or older.
- •Subjects with the following ARID1a mutated, ovarian/fallopian tube/primary peritoneal cancer histologies (ARID1a mutation status determined by a DNA-based Next Generation Sequencing test):
- •Clear cell ovarian carcinoma (≥ 50% clear cell carcinoma with no serous differentiation)
- •Endometrioid ovarian carcinoma
- •Subjects must have disease progression within 6 months (182 days) from completion of platinum-based therapy (6 months should be calculated from the date of the last administered dose of platinum therapy to the date of radiographic imaging showing progression)
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.
- •Subjects with a BRCA mutation must have received prior treatment with a PARP inhibitor.
- •Subjects must have received at least 1 but not more than 3 prior systemic lines of anticancer therapy, including at least 1 line of therapy containing bevacizumab.
- •Adjuvant + neoadjuvant are considered one line of therapy
- •Maintenance therapy (i.e., bevacizumab, PARP inhibitors) will be considered as part of the preceeding line of therapy and are not counted independently.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Subjects must have a sufficient archival Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimen, or be willing to consent to a fresh tissue biopsy during the study.
- •Part B Exclusion Criteria:
- •Subjects with disease that did not respond to, or has progressed during or within 4 weeks of the last dose of first-line platinum containing chemotherapy.
- •Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP
- •Ongoing toxic manifestations of previous treatments > Grade 2, with the exception of alopecia.
- •Subjects with treated brain metastases are eligible if there is no evidence of progression for at least 12 weeks while off corticosteroids after central nervous system (CNS) directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
- •Female subjects who can become pregnant (or are already pregnant or lactating).
Arms & Interventions
Part B: Expansion in Ovarian Cancers Cohort 1
Experimental
Subjects will be treated with NXP800 at 50 mg/day orally.
Intervention: NXP800 (Drug)
Part A: Dose Escalation
Experimental
Escalating doses of NXP800 administered orally once or twice daily.
Intervention: NXP800 (Drug)
Part B: Expansion in Ovarian Cancers Cohort 2
Experimental
Subjects will be treated with NXP800 at 75 mg/day orally.
Intervention: NXP800 (Drug)
Outcomes
Primary Outcomes
Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities
Time Frame: Day 28
Part B: Estimates of disease response by RECIST v 1.1
Time Frame: Baseline to 30 days post last dose of NXP800
Part B: Number of patients with treatment related adverse events, and/or clinical laboratory abnormalities.
Time Frame: Baseline to 30 days post last dose of NXP800
Secondary Outcomes
- Time to peak concentration (Tmax) of NXP800(First dose through Day 29)
- Half-life (T1/2) of NXP800(First dose through Day 29)
- Area under the concentration-time curve (AUC) of NXP800(First dose through Day 29)
- Maximum observed concentration (Cmax) of NXP800(First dose through Day 29)
Investigators
Study Sites (37)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersAdvanced Solid TumorNCT05873686Nuvectis Pharma, Inc.140
Terminated
Phase 1
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary CancerGastric CancerBiliary CancerPancreatic CancerColorectal CancerNCT02908451AbGenomics B.V Taiwan Branch39
Terminated
Phase 1
Safety Study of XL999 in Adults With Non-Small-Cell Lung CancerNon-Small-Cell Lung CancerNCT00491699Symphony Evolution, Inc.2
Terminated
Phase 1
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesB-cell MalignanciesNCT02457598Gilead Sciences203
Completed
Phase 1
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)Carcinoma, Renal CellNCT04846920Merck Sharp & Dohme LLC29